St. Jude’s Portico Transcatheter Aortic Valve Receives CE Mark

St. Jude’s Portico Transcatheter Aortic Valve Receives CE Mark

St. Jude Medical has just announced the first successful human implantation of the company’s Portico transcatheter aortic heart valve in a patient with aortic stenosis. The procedure was performed by Dr. John Webb, director of cardiac catheterization and interventional cardiology at St. Paul’s Hospital in Vancouver, British Columbia. We hear that St.Jude is working hard to make sure the device is safe and secure, so things like perivalvular leaks and valve displacements do not happen during or after implantation. 38djjjlj St. Judes Portico Transcatheter Aortic Valve Implanted in Human (Exclusive Pics)Furthermore, the company is looking into ways to develop both transapical and transfemoral deliveries for the valve. And, in addition, the device, when it is finally approved, might feature the company’s proprietary Linx anticalcification technology that might actually prolong the life of the device and/or prevent calcium buildup and things like embolizations.

Check our exclusive images of the device, and here’s more info about it from the announcement:

The valve, which is made of bovine pericardial tissue, is designed to increase physicians’ control and placement accuracy during valve deployment. The Portico transcatheter heart valve can be completely resheathed (the process of bringing the valve back into the delivery catheter) and retrieved before it is released from the delivery system, allowing physicians to reposition the valve at the implant site. No transcatheter valve currently on the market has the ability to be re-sheathed, repositioned, or retrieved.

The St. Jude Medical transcatheter heart valve was designed for the estimated 400,000 patients with severe aortic stenosis who are considered to be high risk or inoperable for conventional open-heart valve replacement therapy. Two delivery methods will be available for the Portico valve, transfemoral (delivered via the femoral artery) and transapical (delivered via a small incision in the apex of the left ventricle).

Commenting on the first implant, Dr. Gregory Fontana, professor and vice chairman, Department of Surgery at the Cedars-Sinai Heart Institute in Los Angeles, Calif., said, “Many of the shortcomings of first generation devices have been addressed with the next generation St. Jude Medical Portico transcatheter valve.”

In February 2010, St. Jude Medical announced that Dr. Fontana, and Dr. Raj Makkar, director of the Interventional Cardiology and Cardiac Catheterization Laboratory at the Cedars-Sinai Heart Institute, will be the principal investigators in the company’s transcatheter aortic valve implantation (TAVI) clinical trial. The study will evaluate the safety and efficacy of the St. Jude Medical transcatheter aortic valve for patients who experience severe aortic stenosis and who may be at an elevated risk for open-heart surgery.

St. Jude Medical Announces European Approval of the Portico Transcatheter Aortic Heart Valve

ST. PAUL, Minn.–(BUSINESS WIRE)–Nov. 19, 2012– St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced it has received European CE Mark approval for its 23 mm Portico™ Transcatheter Aortic Heart Valve and Transfemoral Delivery System. Designed for patients with severe aortic stenosis who are considered to be inoperable or high risk for conventional open-heart valve replacement surgery, the Portico valve is implanted through a small incision in the femoral artery (the main artery of the leg). The procedure uses a catheter placed percutaneously (through the skin) to deliver and position the valve in the heart and occurs while the heart continues to beat. This avoids the need to place the patient on cardiopulmonary bypass, a process in which a machine takes over heart and lung function during surgery.

23 mm Portico(TM) Transcatheter Aortic Heart Valve – Image courtesy of St. Jude Medical.

23 mm Portico(TM) Transcatheter Aortic Heart Valve – Image courtesy of St. Jude Medical.

The Portico device is the only approved transcatheter valve that can be completely resheathed (the process of bringing the valve back into the delivery catheter), repositioned at the implant site or retrieved before it is released from the delivery system. The valve was designed in collaboration with leading physicians to address limitations of current-generation devices by improving control and accuracy in positioning and placement of the valve, minimizing paravalvular leak (a common complication with first-generation transcatheter valves) and potentially reducing the need for the implantation of a permanent pacemaker after the procedure.

“The ability to completely resheath, reposition or retrieve the Portico valve is an important improvement over previous-generation transcatheter valves,” said Dr. Ganesh Manoharan of Royal Victoria Hospital in Belfast, U.K. “This is particularly helpful in ensuring accurate placement of the valve and minimizing complications for this high risk population.”

Featuring leaflets made of bovine pericardial tissue attached to a self-expanding stent, the Portico valve was designed to help increase physician control and placement accuracy during deployment of the valve.

“The European approval of the Portico transcatheter valve signals the imminent availability of a next-generation treatment option that can help improve quality of life for patients with diseased or damaged aortic heart valves,” said Frank J. Callaghan, president of the St. Jude Medical Cardiovascular and Ablation Technologies Division. “It also represents a key milestone for St. Jude Medical’s transcatheter heart valve program, and exemplifies our focus on developing technologies that advance the practice of medicine.”

Dr. Manoharan recently presented first-in-human (FIH) 12-month data demonstrating the safety and efficacy of the Portico transcatheter heart valve at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. In the study, there were no vascular complications, major strokes or deaths among study patients and no new pacemakers required. Clinical improvements that were noted at earlier follow-up intervals were sustained out to 12 months (including valve function).

St. Jude Medical also intends to begin a European study of the 25 mm valve to support CE Mark approval before the end of the year.

For additional information about the Portico valve visit SJMPortico.com.

About St. Jude Medical

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and Quarterly Report on Form 10-Q for the fiscal quarter ended September 29, 2012. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Comprehensive Approach, Accurate Placement

The Portico system provides a unique, truly comprehensive approach to aortic valve implantation designed to optimize outcomes with:

Full resheathability*

Positioning flexibility to improve placement accuracy

Minimal protrusion into the LVOT

Ability to retrieve* the valve if needed

Targeted Placement

Uniquely Designed for Positioning to Address the Risk of Heart Block and PV Leak

Designed to address conduction system interference by placing the valve low within the stent frame which allows for sealing without the valve extending deep into the LVOT

The large cells in the annulus section of the stent are designed to minimize the risk of PV Leak:

Less metal – minimizing the potential of a stent strut resting against a calcific nodule

More tissue – allowing the tissue to conform around calcific nodules

Efficient Loading and Prep

Unique loading tools allow for fast and easy valve loading and prep

Loading and prep are performed at room temperature

Total rinse time for the valve is only 20 seconds

Source : http://investors.sjm.com/phoenix.zhtml?c=73836&p=irol-newsArticle&ID=1760178

Related Posts Plugin for WordPress, Blogger...
Be Sociable, Share!

About the Author

has written 1822 posts on this blog.

Copyright © 2017 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes